Home > Boards > US Listed > Medical - Drugs > Flexion Therapeutics, Inc. (FLXN)

Good day here... Closed at 17.23 / +50.48%

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Book Em Dan O Member Profile
 
Followed By 18
Posts 482
Boards Moderated 0
Alias Born 09/17/10
160x600 placeholder
Statement of Ownership: Solicitation (sc 14d9) Edgar (US Regulatory) - 10/22/2021 6:49:36 AM
Tender Offer Statement by Third Party (sc To-t) Edgar (US Regulatory) - 10/22/2021 6:07:48 AM
Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) Edgar (US Regulatory) - 10/12/2021 4:17:03 PM
Written Communication Relating to an Issuer or Third Party (sc To-c) Edgar (US Regulatory) - 10/12/2021 6:08:45 AM
Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc. PR Newswire (US) - 10/11/2021 4:26:00 PM
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management GlobeNewswire Inc. - 10/11/2021 7:00:00 AM
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management GlobeNewswire Inc. - 10/11/2021 7:00:00 AM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 10/1/2021 4:30:00 PM
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire Inc. - 9/8/2021 4:30:00 PM
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference GlobeNewswire Inc. - 9/3/2021 9:00:00 AM
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee GlobeNewswire Inc. - 9/2/2021 7:30:00 AM
Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating FX301 for the Management of Post-Operative Pain GlobeNewswire Inc. - 8/25/2021 7:30:00 AM
Flexion Therapeutics Announces Publication of Results from Phase 2 Pharmacokinetics (PK) and Safety Study of ZILRETTA® in Shoulder Osteoarthritis (OA) GlobeNewswire Inc. - 8/9/2021 4:30:00 PM
Flexion Therapeutics EPS beats by $0.06, misses on revenue; reiterates guidance Seeking Alpha - 8/4/2021 5:09:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/4/2021 4:12:16 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2021 4:10:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2021 4:03:37 PM
Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights GlobeNewswire Inc. - 8/4/2021 4:01:00 PM
Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021 GlobeNewswire Inc. - 7/29/2021 4:15:00 PM
Flexion Therapeutics adds Utpal Koppikar to its board of directors Seeking Alpha - 7/12/2021 4:42:43 PM
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors GlobeNewswire Inc. - 7/12/2021 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/12/2021 4:07:02 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/12/2021 4:04:55 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/6/2021 4:35:25 PM
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 7/2/2021 4:30:00 PM
Book Em Dan O   Thursday, 05/26/16 04:12:15 PM
Re: None
Post # of 70 
Good day here... Closed at 17.23 / +50.48% / 2,325,575 shares traded

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences